Combination therapy for her2-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of drugs (including an investigational drug called KN026) for people with HER2-positive stomach cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with stomach cancer that cannot be surgically removed or has spread to other parts of the body.
- You have not received prior treatment for this cancer, or if you had surgery or radiation before, it was more than 6 months ago and the cancer has come back.
- Your cancer tests positive for HER2 (a protein that helps cells grow).
- You are generally able to take care of yourself and are up and about at least half the day (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
This trial tests a new drug called JSKN003 for people with HER2-positive stomach cancer. It may be used as a first treatment for advanced cancer or before surgery for cancer that can be removed. The goal is to see if the drug helps shrink or control the cancer.
This trial tests a combination of immunotherapy (serplulimab), a targeted HER2 therapy (trastuzumab), and chemotherapy (SOX) after stomach cancer surgery. The goal is to see if this combination reduces the chance of cancer returning in people with HER2-positive stomach cancer.
This trial tests a new combination of two drugs for stomach cancer that has spread and shows a specific protein (HER2). The goal is to see if the combination helps patients who haven't had treatment for advanced disease.
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
Hear when a new HER2-positive Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.